Acrivon Therapeutics, Inc. (ACRV) vs ImmuCell Corporation (ICCC)
Acrivon Therapeutics, Inc. and ImmuCell Corporation are both Biotechnology companies. Acrivon Therapeutics, Inc. and ImmuCell Corporation are of similar size ($90.9M and $90.6M). Acrivon Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; ImmuCell Corporation trades at 117×. ImmuCell Corporation has the higher net margin (2.57% vs 0.00%) and the higher return on invested capital (7.84% vs 0.00%). Across the 15 metrics below, ImmuCell Corporation leads on 11 and Acrivon Therapeutics, Inc. on 4.
Valuation
Profitability
| Metric | ACRV | ICCC | Biotechnology median |
|---|---|---|---|
| Gross margin | 0.00% | 40.32% | 65.16% |
| Operating margin | 0.00% | 12.60% | 0.00% |
| Net margin | 0.00% | 2.57% | 0.00% |
| Free cash flow margin | 0.00% | 13.79% | 0.00% |
| Return on equity | (64.63%) | 2.57% | (57.72%) |
| Return on assets | (57.61%) | 1.69% | (49.22%) |
| Return on invested capital | 0.00% | 7.84% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack